Why Medication Alone Falls Short in Alzheimer’s Care

Most families navigating an Alzheimer’s diagnosis ask the same question early on: are these medications going to be enough? It is a fair question. Prescription drugs are typically the first thing offered after diagnosis, and the conversation rarely extends much beyond them.

The honest answer is that current Alzheimer’s medications matter — and they are not enough on their own. Cholinesterase inhibitors and NMDA receptor antagonists modestly slow symptom progression for some patients. Newer anti-amyloid drugs like lecanemab and donanemab can slow disease progression by clearing amyloid plaques. None of them, however, address the broader biological landscape that drives cognitive decline — and that landscape is where the most powerful interventions live.

The framing that serves families best is not “medication versus lifestyle.” It is “medication alone versus medication combined with a precision-medicine approach.” This article explains what current Alzheimer’s drugs do and don’t do, what they miss, and how a residential precision-medicine program — like the ReCODE+ For Facilities Program at Michigan Cognitive Recovery Center — fills the gaps medication leaves behind. For an overview of the underlying framework, see our guide to precision medicine for early-stage Alzheimer’s.

Quick Facts

Current medication classes: cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonists (memantine), and anti-amyloid drugs (lecanemab, donanemab).What they do: symptomatic improvement and modest slowing of disease progression. Anti-amyloid drugs modify the disease itself by clearing amyloid plaques.What they don’t address: inflammation, lack of hormones and nutrients, metabolic dysfunction, toxin exposures, vascular dysfunction, and traumatic brain injuries — the six biological contributors investigated in the ReCODE Protocol.The better question: not “drugs or no drugs?” but “drugs alone, or drugs combined with a precision-medicine approach?”In Michigan: Michigan Cognitive Recovery Center delivers the residential ReCODE+ For Facilities Program at 4851 Lakeshore Rd, Fort Gratiot Township, MI 48059. 810-385-3185.

What Current Alzheimer’s Medications Actually Do

Three classes of medication are commonly used today. Each targets a single mechanism, and each delivers a different kind of benefit.

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)

These drugs slow the breakdown of acetylcholine, a neurotransmitter important for memory and learning. They are typically prescribed in mild-to-moderate Alzheimer’s and can produce modest symptomatic improvement in attention, memory, and daily function for some patients. The benefit tends to plateau over time, and effects vary widely from person to person.

NMDA receptor antagonists (memantine)

Memantine acts on a different brain receptor system involved in learning and memory and is typically used in moderate-to-severe stages, sometimes alongside a cholinesterase inhibitor. Like that class, it offers modest symptomatic benefit rather than disease modification.

Anti-amyloid drugs (lecanemab, donanemab)

Recently FDA-approved monoclonal antibodies that target and remove amyloid plaques from the brain. Unlike the older symptomatic medications, these are disease-modifying — they don’t just mask symptoms; they alter the biology of the disease. Clinical trials have shown they can slow cognitive decline in early-stage patients, though the magnitude is modest and they carry risks (notably brain swelling and bleeding) that require monitoring with regular MRIs. They are also expensive and not appropriate for every patient.

What Medication Doesn’t Address

Each of these drug classes targets one mechanism. Alzheimer’s, however, is increasingly understood as a multi-factorial disease — the result of multiple biological processes operating at once. According to Apollo Health, the ReCODE Protocol identifies and addresses six categories of biological contributors to cognitive decline, none of which are addressed by current medications:

• Inflammation — chronic neuroinflammation driven by infections, gut health, or immune activation.
• Lack of hormones and nutrients — including thyroid, sex hormones, vitamin D, and B vitamins.
• Metabolic dysfunction — insulin resistance and impaired glucose use in the brain.
• Toxin exposures — mycotoxins from mold, heavy metals, environmental chemicals.
• Vascular dysfunction — reduced blood flow, sleep apnea, untreated cardiovascular risk factors.
• Traumatic brain injuries — past head injuries that create long-term cognitive vulnerability.

Each contributor that is identified and addressed is one less driver of decline. Medication alone does not investigate any of these; it acts downstream of all of them.

Why a Single-Mechanism Approach Falls Short

Decades of pharmaceutical research have followed the same pattern: identify one mechanism, develop a drug, run a trial, hope for a meaningful effect. Hundreds of single-mechanism Alzheimer’s trials have produced disappointing results. The newest disease-modifying drugs slow progression but do not reverse it.

A precision-medicine approach inverts the question. Instead of asking “what one drug treats Alzheimer’s?” it asks “which of the six biological drivers are active in this person, and how do we address each one?” The answer is rarely a single intervention. It is comprehensive testing followed by personalized changes across nutrition, sleep, exercise, hormones, supplements, detoxification, and stress management — supported, where appropriate, by medication.

Published research on this approach is encouraging. According to Apollo Health, two clinical studies have reported 75–84% of early-stage participants experienced measurable cognitive improvement on the ReCODE Protocol, and a 2025 randomized controlled trial reported 90% improvement and an effect size 600% greater than the leading FDA-approved Alzheimer’s drug. For the full clinical context, see our guide to ReCODE residential care in Michigan.

Side Effects and Adherence Realities

Medication considerations don’t end with “does it work?” Families also navigate side effects and the daily reality of medication management.

• Cholinesterase inhibitors commonly cause nausea, vomiting, diarrhea, weight loss, sleep disturbances, and dizziness. For some patients these are tolerable; for others they are limiting.
• Memantine is generally better tolerated but can cause dizziness, headache, confusion, and constipation.
• Anti-amyloid drugs require infusions every two to four weeks and ongoing MRI monitoring for amyloid-related imaging abnormalities (ARIA), which can be serious in some cases.

None of these are reasons to avoid medication when it is appropriate. They are reasons to think about Alzheimer’s care as a comprehensive plan rather than a prescription pad — and to make decisions in partnership with a qualified clinician who knows the individual patient.

How a Precision-Medicine Program Complements Medication

Precision medicine and Alzheimer’s drugs are not opposites. In a residential program like MCRC’s, they work together:

• Comprehensive testing identifies which of the six biological drivers are active in each resident.
• A personalized care plan addresses each identified driver — through targeted nutrition, exercise, sleep optimization, stress management, brain stimulation, detoxification support, and personalized supplementation.
• Medication continues when prescribed by the resident’s clinician, with ongoing monitoring of effectiveness, side effects, and interactions.
• Continuous biomarker re-testing shows what is working and what needs adjustment, with care plans evolving over the 12-month program.

The lifestyle pillars in this approach are the same ones general prevention research supports — and going much deeper. For an introduction to those foundations, see our guide to lifestyle changes for brain health and our guide to the KetoFLEX 12/3 diet.

Medication Alone vs. Medication Combined with a Precision-Medicine Program

Question	Medication alone	Medication + ReCODE+ residential program
What does it target?	One mechanism per drug class	All six biological contributors plus medication, when prescribed
How is the plan personalized?	Generally not — same medication, dose-adjusted	Personalized testing → individualized ReCODE Report™
How is progress monitored?	Periodic clinical visits	Continuous biomarker and cognitive re-testing
Does it address lifestyle?	Not directly	Yes — daily implementation of all seven Bredesen pillars
Implementation burden on family	Mostly the family carries it	24/7 trained dementia-care staff handle daily implementation

What This Looks Like at Michigan Cognitive Recovery Center

Michigan Cognitive Recovery Center at Lakeshore Woods Senior Living is one of only two U.S. facilities offering the ReCODE+ For Facilities Program. The 12-month residential program serves adults with subjective cognitive impairment (SCI), mild cognitive impairment (MCI), or early-stage Alzheimer’s.

What that means for families navigating the medication question:

• Medication continues when prescribed by the resident’s primary clinician — MCRC works with the existing care team, not around it.
• Comprehensive baseline testing identifies the biological drivers behind that resident’s decline, which medication alone never investigates.
• The Bredesen Seven — nutrition (KetoFLEX 12/3), exercise, sleep optimization, stress management, brain stimulation, detoxification, and targeted supplementation — runs daily under trained staff.
• 24/7 dementia-care support handles the practical implementation that families struggle to maintain at home.
• Family communication and education keeps caregivers informed and supported throughout the program, including what to continue after the residential phase ends.

Comprehensive Alzheimer’s Care in Michigan

MCRC serves families across Michigan from its Fort Gratiot location at 4851 Lakeshore Rd, including Port Huron, Marysville, Burtchville, Lexington, and the rest of St. Clair County, plus families traveling from Macomb County, Oakland County, and metro Detroit. A second Michigan location is opening soon at Fenton Woods, expanding access for families in Fenton, Linden, Holly, Grand Blanc, Flint, and Genesee County.

To learn more or schedule a tour of the Birch Building at Lakeshore Woods, call 810-385-3185 or visit michigancognitiverecovery.com.

What This Means for Families Right Now

If your loved one is currently on Alzheimer’s medication, that doesn’t need to change. The question worth asking is whether medication is doing all the work — or whether the underlying biological drivers are being addressed at the same time. For early-stage families, timing matters more than severity — and the earlier a comprehensive evaluation begins, the more drivers can still be reversed.

Frequently Asked Questions

Wondering whether medication alone is doing enough? Call Michigan Cognitive Recovery Center at 810-385-3185 or visit michigancognitiverecovery.com to schedule an evaluation or a tour of the Birch Building at Lakeshore Woods.

Disclaimer: This content is for educational purposes only and does not constitute medical advice. Decisions about Alzheimer’s medications should always be made with a qualified prescribing clinician who knows the patient. The ReCODE Protocol is a precision-medicine program delivered by Apollo Health-trained practitioners and is not a cure for Alzheimer’s disease. Outcomes vary by individual. For complete clinical information, please visit Apollo Health.

About the author. This article was written by the Lakeshore Woods Team. Lakeshore Woods Senior Living is a 78-bed senior living community in Fort Gratiot Township, Michigan, and the home of Michigan Cognitive Recovery Center — one of only two U.S. senior living centers that offers the ReCODE+ For Facilities Program in partnership with Apollo Health. For complete clinical information, please visit Apollo Health.